Lyell Immunopharma, Inc.
LYEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -53.1% | -99.8% | 695.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -328,923% | -174,429.2% | -199.6% | -1,888.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -562,285.2% | -180,486.2% | -216.2% | -2,349.5% |
| EPS Diluted | -1.31 | -0.935 | -0.741 | -1.031 |
| % Growth | -40.1% | -26.1% | 28.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |